Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

Under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s submission of a Type II Drug Master File (DMF) to the FDA
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors

January 5, 2024 — NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and ...

Time January 05, 2024
arrow
Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer
News | Radiology Business
Nucleus RadioPharma Appoints Former McKesson, Novo Nordisk Executive Kathy Spencer-Pike as Chief Commercial Officer to Drive Business Growth

December 14, 2023 — Nucleus RadioPharma, a fully integrated development, manufacturing, and supply chain organization ...

Time December 14, 2023
arrow
Rigging of the Cyclone 30XP in Poland completed with a further two sites in Germany and France already operational
News | Radiopharmaceuticals and Tracers
IBA Pioneers Theranostic Advancements, Empowering the Market to Produce Astatine-211

December 12, 2023 — IBA, a world leader in particle accelerator technology and of radiopharmaceutical production ...

Time December 12, 2023
arrow
Licensing agreement between Philochem and Blue Earth Diagnostics, one of the Bracco family of companies, encompasses applications of OncoFAP for diagnostic and medical imaging
News | Radiopharmaceuticals and Tracers
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4
News | Radiopharmaceuticals and Tracers
Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
New company will advance Actinium-225 technologies
News | Radiopharmaceuticals and Tracers
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

Time October 18, 2023
arrow
Radionetics initiates its first clinical program targeting MC2R
News | Radiation Oncology
Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

October 17, 2023 — Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and ...

Time October 17, 2023
arrow
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics - [68Ga]FAPI-46 and outside-U.S. rights for [18F]FAPI-74
News | Radiopharmaceuticals and Tracers
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...

Time October 11, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.
News | Radiopharmaceuticals and Tracers
Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

October 5, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 05, 2023
arrow
POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

September 27, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 27, 2023
arrow
This molecule may significantly expand the patient population eligible for SCINTIX therapy to patients with solid tumor cancers of any stage in a manner that may improve both outcomes and procedural workflow
News | Radiation Therapy
RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
The iba Cyclone IKON
Feature | PET Imaging
PET Radiotracer Market anticipated to reach $3.2 Billion in Revenues by 2031

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
arrow
NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 31, 2023
arrow
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

August 29, 2023 — NorthStar Medical Radioisotopes, LLC (“NorthStar"), a global innovator in the development, production ...

Time August 29, 2023
arrow
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
Carolina Breast Imaging Specialists, PLLC Is First in Nation to Adopt Groundbreaking Imagio Breast Imaging System for Breast Cancer Diagnosis

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

Time August 29, 2023
arrow
Strategic collaboration signed to support the development of radiopharmaceuticals in the fight against cancer
News | Radiopharmaceuticals and Tracers
PanTera and TerraPower Isotopes Join Forces to Accelerate Access to Actinium-225

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
arrow
FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States
News | Prostate Cancer
Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 28, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers. 
News | Radiopharmaceuticals and Tracers
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 25, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 25, 2023
arrow
Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of its teams at the PI-CAI (Prostate Imaging: Cancer Al) Grand Challenge
News | Prostate Cancer
Guerbet Wins PI-CAI Grand Challenge on Detection of Prostate Cancer

July 19, 2023 — Guerbet, a global specialist in contrast media and medical imaging solutions, announced the success of ...

Time July 19, 2023
arrow
A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers
News | Radiopharmaceuticals and Tracers
First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 11, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

Time July 11, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now